James Bucher
Consejero General en HARPOON THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de James Bucher
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
HARPOON THERAPEUTICS, INC. | Consejero General | 26/12/2023 | - |
Historial de carrera de James Bucher
Antiguos cargos conocidos de James Bucher.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
EXELIXIS, INC. | Consejero General | 01/01/2007 | 01/01/2014 |
Secretario Corporativo | 01/01/2007 | 01/01/2014 | |
Shearman & Sterling LLP
Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/1991 | 01/01/2007 |
ELIEM THERAPEUTICS, INC. | Consejero General | 01/10/2020 | - |
Secretario Corporativo | - | - | |
ALDER BIOPHARMACEUTICALS, INC. | Consejero General | 06/10/2016 | - |
Formación de James Bucher.
Emory University School of Law | Graduate Degree |
Colgate University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Italia | 2 |
Operativa
General Counsel | 4 |
Corporate Secretary | 2 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
EXELIXIS, INC. | Health Technology |
ELIEM THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Shearman & Sterling LLP
Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Commercial Services |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- James Bucher
- Experiencia